SD-1008
Product Specifications
UNSPSC Description
SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway[1].
Target Antigen
Apoptosis; JAK; STAT
Type
Reference compound
Related Pathways
Apoptosis;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sd-1008.html
Solubility
10 mM in DMSO
Smiles
O=C([C@H]1[C@H](C2=O)N([C@H](C=C2)[C@H]1C(OC)=O)CC3=CC=CC=C3)OC
Molecular Weight
329.35
References & Citations
[1]Duan Z, et al. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol. 2007;72(5):1137-1145.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-107595/SD-1008-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-107595/
Clinical Information
No Development Reported
CAS Number
960201-81-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
